



Evolution of Faecal Microbiota Transplant (FMT): From Early Clinical to Standardized Treatments

A Virtual Meeting

15:00 - 18:00 CEST // 9:00am - 12:00pm EDT

15:00-15:05	IABS Welcome	Joris VANDEPUTTE, President, IABS
15:05-15:10	BIOASTER Welcome	Cyril GUYARD, Deputy Chief Scientific Officer, Director of Research Programs, Bioaster
15:10-15:35	Developing global standards for the microbiome field	Chrysi SERGAKI, NIBSC, United Kingdom
15:35-16:00	Current and emerging indications of FMT: Can it really be a standardized treatment ?	Harry SOKOL, INSERM CRSA UMRS 938, Sorbonne University, France
16:00-16:25	Fecal Microbiota Transfer : From Bench to Bedside	Hervé AFFAGARD, MaaT Pharma, France
16:25-16:50	New strategies for stratification and longitudinal monitoring of microbiota	Vincent THOMAS, BIOASTER, France
	Panel Discussion	
	Facilitator: Stephanie Servetas, NIST	<ul style="list-style-type: none">• Chrysi SERGAKI, NIBSC, United-Kingdom• Harry SOKOL, INSERM CRSA UMRS 938, Sorbonne University, France• Hervé AFFAGARD, Maat Pharma, France• Vincent THOMAS, BIOASTER, France• Jennifer WARGO, MD Anderson Cancer Center, U.S.A.• Gary WU, University of Pennsylvania, U.S.A.
17:50-18:00	Webinar Wrap-up	Stephanie Servetas, NIST
18:00	Closing Statements	Joris VANDEPUTTE, President, IABS